Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Probucol protects lipoprotein (a) against oxidative modification.

M Naruszewicz1, E Selinger, R Dufour

  • 1Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec, Canada.

Metabolism: Clinical and Experimental
|November 1, 1992
PubMed
Summary

Probucol treatment enhanced resistance of low-density lipoprotein (LDL) and lipoprotein(a) [Lp(a)] to oxidation and macrophage uptake. This suggests probucol may counteract the atherogenic potential of oxidized Lp(a).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of neutrophils and proinflammatory cytokines in the mechanism of inflammatory bowel diseases - what have we learned from experimental models of colitis in rodents?

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2026
Same author

Epigenetic View on Interferon γ Signalling in Tumour Cells.

Folia biologica·2019
Same author

Anthropometric measures and their association with risk factors for cardio-metabolic diseases in Kenyan adults.

Annals of human biology·2019
Same author

LITHIUM FLUORIDE CRYSTALS AS FLUORESCENT NUCLEAR TRACK DETECTORS.

Radiation protection dosimetry·2017
Same author

A Chart Abstraction Based Method to Classify Real World Patients With Pulmonary Arterial Hypertension Based on Who Functional Classification.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.

Molecular psychiatry·2014

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • Familial combined hyperlipidemia is associated with high lipoprotein(a) [Lp(a)] levels.
  • Oxidized low-density lipoprotein (LDL) and Lp(a) exhibit increased atherogenic potential.
  • Probucol is known for cholesterol-lowering and antioxidant effects.

Purpose of the Study:

  • To investigate the effect of probucol on Lp(a) and LDL oxidation and macrophage interaction.
  • To determine if probucol administration alters the atherogenic properties of Lp(a) and LDL.

Main Methods:

  • Oral administration of probucol to patients with familial combined hyperlipidemia and high Lp(a).
  • In vitro assessment of LDL and Lp(a) oxidation by copper.
  • Macrophage uptake and degradation assays for LDL and Lp(a) before and after probucol treatment.

Related Experiment Videos

Main Results:

  • Probucol did not alter Lp(a) concentrations but was found in both Lp(a) and LDL.
  • Post-treatment LDL and Lp(a) showed increased resistance to in vitro oxidation.
  • Probucol inhibited enhanced macrophage uptake and degradation of oxidized LDL and Lp(a).

Conclusions:

  • Probucol confers resistance to LDL and Lp(a) oxidation.
  • Probucol may mitigate the atherogenic risk associated with oxidized Lp(a).
  • Further research is warranted to explore probucol's role in managing hyperlipidemia and atherosclerosis.